Google
RANI — RANI THERAPEUTICS HOLDINGS INC (Healthcare >> Biotechnology)
RANI FAQ
What is RANI's ROE?
RANI THERAPEUTICS HOLDINGS INC reports a Return on Equity (ROE) of -103.65%.
What is RANI's dividend yield?
RANI THERAPEUTICS HOLDINGS INC offers a dividend yield of 0.00%.
What is RANI's Deepscope Quality Score?
Deepscope rates RANI's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy RANI?
Deepscope's AI Timing Score for RANI is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does RANI belong to?
RANI THERAPEUTICS HOLDINGS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 0.90
Price
0.02
(2.69%)
Day Change
|
|
|---|
RANI, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 96 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.90 |
| PBV / Sector |
3.32 / 4.58
|
| Earning Per Share | -0.22 |
| PE / Sector |
N/A / 17.10
|
| PEG or PE/Growth / Sector |
N/A / 0.52
|
| Average 1M Daily Value |
1.20 M
GREAT
|
| Average 1W Daily Value |
1.05 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
52% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-05 09:11:58 |
| Symbol | RANI |
| Name | RANI THERAPEUTICS HOLDINGS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 112.39 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 117.92 / 8,655.90 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2051 Ringwood Avenue, San Jose, CA, United States, 95131
Phone: 408 457 3700
Website: https://www.ranitherapeutics.com
Employees: 69
Sector: Healthcare >> Biotechnology
Description: Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The have a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity; and Chugai Pharmaceutical Co., Ltd. to commercialize the Chugai Product combining Chugai's Compound, which is in development for hemophilia, and the RaniPill HC oral delivery device for use in humans. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
